3-MMC

From PsychonautWiki
Jump to: navigation, search
3-MMC
The skeletal formula of 3-MMC
3-MMC.png
Chemical Nomenclature
Common names 3-MMC
Substitutive name 4-methylmethcathinone, 3-methylephedrone
Systematic name (RS)-2-​(methylamino)-​1-​(3-​methylphenyl)-​1-​propanone
Class Membership
Psychoactive class Stimulant, Entactogen
Chemical class Cathinone
Routes of Administration



Oral
Dosage
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
This dosage and duration information has been sourced from TripSit
Threshold 10 - 25 mg
Light 25 - 75 mg
Common 75 - 150 mg
Strong 150 - 300 mg
Heavy 300 mg +
Duration
Total 4 - 7 hours
Peak 2 - 3 hours
Offset 30 - 60 minutes
After effects 3 - 4 hours









3-MMC (3-Methylmethcathinone) is a short-acting stimulant of the phenethylamine, amphetamine and cathinone classes. Its effects are very similar to those of mephedrone (4-MMC) but less euphoric, making it the less popular substitution of the two.

Chemistry

Molecule.svg

This chemistry section is incomplete.

You can help by adding to it.

Pharmacology

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based upon its structure and subjective effect similarities to other stimulants such as mephedrone, amphetamine and 2-FMA. 3-MMC most likely acts as both a dopamine and norepinephrine releasing agent. This means it may effectively boost the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.

Subjective effects

Metacogghjgjvghnition.png
This subjective effect breakdown is a stub.

As such, it may contain incomplete or wrong information and is still in progress.

You can help by expanding it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

Cognitive effects

Auditory effects

Toxicity and harm potential

As with all research chemicals, the long-term effects of 3-MMC haven’t been researched extensively enough to provide accurate information of its risks and harm.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of 3-MMC can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. It is said that this compound is considerably more addictive than that of mephedrone.

Tolerance to many of the effects of 3-MMC develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MMC presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 3-MMC all stimulants will have a reduced effect.

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Serotonin syndrome risk

Combinations in the list below may increase the amount of neurotransmitters such as serotonin and dopamine to dangerous or even fatal levels.

Legal issues

Handcuffs-300px.png

This legality section is a stub.

As such, it likely contains incomplete or wrong information. You can help by expanding it.

Up until recently, 3-MMC was legally and easily obtainable to most people by ordering online. Some countries had found ways to include it within other drug acts, but most had not banned the specific chemical nor included its structure or use within bigger law articles.[2]

  • China - Since October 2015, the drug has been banned (along with an enormous amount of other chemicals) in China. Due to this ban, many chemicals have become increasingly difficult to attain since the manufacturing was mainly done by Chinese chemical companies.[3]
  • Czeck republic - 3-MMC is banned in the Czech Republic.[4]
  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[5]
  • Germany - On December 13th, 2014, 3-MMC was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.[6]

Experience reports

Anecdotal reports which describe this compound within our experience index include:

See also

External links

References

  1. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
  2. THE STATE OF THE DRUGS PROBLEM IN EUROPE (p27) | http://www.emcdda.europa.eu/attachements.cfm/att_190854_EN_TDAC12001ENC_.pdf
  3. 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html
  4. http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf
  5. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  6. Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm